NewAmsterdam Pharma Company NAMS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $490M-36.5% | $771.74M+127% | $340.45M-27.2% | $467.73M— | ||
| $146.24M+134% | $62.45M— | —— | —— | ||
| $1.32M— | —— | —— | —— | ||
| $38.14M+57.1% | $24.27M+283% | $6.34M-38.1% | $10.25M— | ||
| $675.7M-21.7% | $863.41M+149% | $346.79M-27.4% | $477.98M— | ||
| $383K+58.3% | $242K+426% | $46K+35.3% | $34K— | ||
| $185K-57.1% | $431K+684% | $55K-54.2% | $120K— | ||
| $407K-23.8% | $534K+214% | $170K-18.3% | $208K— | ||
| $769.28M-11.0% | $864.62M+149% | $347.1M-27.5% | $478.5M— | ||
| $24.58M-3.9% | $25.59M+181% | $9.1M-41.1% | $15.46M+136% | ||
| $3.99M-33.6% | $6.01M+490% | $1.02M-78.7% | $4.79M— | ||
| $136K-44.7% | $246K+310% | $60K-9.1% | $66K— | ||
| $85.79M-19.8% | $106.92M+114% | $49.9M+38.4% | $36.06M— | ||
| $66K-67.3% | $202K— | —— | $60K— | ||
| $85.85M-19.9% | $107.12M+82.5% | $58.7M+21.2% | $48.43M— | ||
| $14.28M+6.2% | $13.44M+32.2% | $10.17M+1.2% | $10.06M— | ||
| $1.43B+9.9% | $1.3B+120% | $590.77M+6.3% | $555.63M— | ||
| -$762.39M-36.5% | -$558.57M-76.2% | -$316.97M-126% | -$140.04M— | ||
| $4.79M+7.3% | $4.47M+1.0% | $4.42M0.0% | $4.42M— | ||
| $683.43M-9.8% | $757.5M+163% | $288.39M-32.9% | $430.07M+478% | ||
| $769.28M-11.0% | $864.62M+149% | $347.1M-27.5% | $478.5M— | ||
| $146.24M+134% | $62.45M— | —— | —— | ||
| $407K-23.8% | $534K+214% | $170K-18.3% | $208K— | ||
| $185K-57.1% | $431K+684% | $55K-54.2% | $120K— | ||
| $407K-23.8% | $534K+214% | $170K-18.3% | $208K— | ||
| $185K-57.1% | $431K+684% | $55K-54.2% | $120K— | ||
| $185K-57.1% | $431K+684% | $55K-54.2% | $120K— | ||
| $15.42M+13.3% | $13.61M+19.4% | $11.4M+86.3% | $6.12M— | ||
| $3.99M-33.6% | $6.01M-32.8% | $8.94M-35.5% | $13.87M— | ||
| $57.27M+52.7% | $37.51M+198% | $12.57M+203% | $4.15M— | ||
| $57.27M+52.7% | $37.51M+198% | $12.57M+203% | $4.15M— | ||
| $202K-54.9% | $448K+647% | $60K-52.4% | $126K— | ||
| $1.43B+9.9% | $1.3B+120% | $590.77M+6.3% | $555.63M— | ||
| $14.28M+6.2% | $13.44M+32.2% | $10.17M+1.2% | $10.06M— | ||
| —— | —— | $35K-77.6% | $156K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can NewAmsterdam Pharma Company cover its short-term obligations?
- Its current ratio is 9.76 — current assets exceed current liabilities.
- Where does NewAmsterdam Pharma Company's balance sheet data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.